Literature DB >> 19118553

Normal cortical excitability in Myoclonus-Dystonia--a TMS study.

S M A van der Salm1, A F van Rootselaar, E M J Foncke, J H T M Koelman, L J Bour, K P Bhatia, J C Rothwell, M A J Tijssen.   

Abstract

OBJECTIVE: The aim of the present study is to investigate cortical excitability in patients with DYT 11 positive Myoclonus-Dystonia (M-D), using transcranial magnetic stimulation (TMS).
METHODS: Silent period, motor evoked potential (MEP) recruitment curve, short interval intracortical inhibition (SICI), intracortical facilitation (ICF) and short interval intracortical facilitation (SICF), with short interstimulus intervals (ISIs) ranging from 1.2 to 3.2 ms, were studied in 15 DYT 11-positive M-D patients and their matched controls. In four patients and matched controls peripheral double pulse electrical nerve stimulation was performed.
RESULTS: All TMS parameters of cortical excitability were normal compared to healthy controls. In the SICF protocol we observed more variable and polyphasic MEPs in M-D patients. Cross-covariance analysis of MEP area revealed a significant correlation difference at ISI 2.2 and 2.8 ms. This increased variability was not seen in other TMS protocols or with peripheral nerve stimulation.
CONCLUSIONS: In contrast with other types of dystonia, no changes in cortical excitability were found in DYT 11 patients. Our findings suggest that M-D is both clinically and pathophysiologically a separate entity from other dystonic disorders. Polyphasic MEPs during the SICF protocol in M-D patients could reflect central neuron membrane instability. Application of the SICF protocol in other patient groups has to prove its value in movement disorders.

Entities:  

Mesh:

Year:  2008        PMID: 19118553     DOI: 10.1016/j.expneurol.2008.12.001

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  8 in total

1.  Abnormal nuclear envelopes in the striatum and motor deficits in DYT11 myoclonus-dystonia mouse models.

Authors:  Fumiaki Yokoi; Mai T Dang; Tong Zhou; Yuqing Li
Journal:  Hum Mol Genet       Date:  2011-11-11       Impact factor: 6.150

2.  Neurophysiological and Genetic Findings in Patients With Juvenile Myoclonic Epilepsy.

Authors:  Stefani Stefani; Ioanna Kousiappa; Nicoletta Nicolaou; Eleftherios S Papathanasiou; Anastasis Oulas; Pavlos Fanis; Vassos Neocleous; Leonidas A Phylactou; George M Spyrou; Savvas S Papacostas
Journal:  Front Integr Neurosci       Date:  2020-08-20

3.  Clinical and neurophysiological profile of four German families with spinocerebellar ataxia type 14.

Authors:  Christos Ganos; Simone Zittel; Martina Minnerop; Odette Schunke; Christina Heinbokel; Christian Gerloff; Christine Zühlke; Peter Bauer; Thomas Klockgether; Alexander Münchau; Tobias Bäumer
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

4.  Automated-parameterization of the motor evoked potential and cortical silent period induced by transcranial magnetic stimulation.

Authors:  Christopher A Rábago; Jack L Lancaster; Shalini Narayana; Wei Zhang; Peter T Fox
Journal:  Clin Neurophysiol       Date:  2009-06-25       Impact factor: 3.708

5.  Motor evoked potential polyphasia: a novel endophenotype of idiopathic generalized epilepsy.

Authors:  Fahmida A Chowdhury; Adam D Pawley; Bryan Ceronie; Lina Nashef; Robert D C Elwes; Mark P Richardson
Journal:  Neurology       Date:  2015-03-04       Impact factor: 9.910

Review 6.  Myoclonic Disorders.

Authors:  Olaf Eberhardt; Helge Topka
Journal:  Brain Sci       Date:  2017-08-14

7.  Basal ganglia modulation of thalamocortical relay in Parkinson's disease and dystonia.

Authors:  Yixin Guo; Choongseok Park; Robert M Worth; Leonid L Rubchinsky
Journal:  Front Comput Neurosci       Date:  2013-09-05       Impact factor: 2.380

8.  Clinical Value of the Assessment of Changes in MEP Duration with Voluntary Contraction.

Authors:  Marisa Brum; Christopher Cabib; Josep Valls-Solé
Journal:  Front Neurosci       Date:  2016-01-11       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.